Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on UroGen Pharma (NASDAQ:URGN) but has reduced the price target from $33 to $32.

November 15, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on UroGen Pharma but lowers the price target from $33 to $32.
While the Outperform rating suggests confidence in UroGen Pharma's prospects, the reduction in price target may indicate a slight adjustment in expectations, possibly due to market conditions or company performance. This mixed signal could lead to a neutral short-term impact on the stock price as the market digests the information.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100